State Street Corp lowered its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 7.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 728,770 shares of the specialty pharmaceutical company’s stock after selling 55,263 shares during the period. State Street Corp owned approximately 1.22% of Jazz Pharmaceuticals PLC worth $105,779,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in shares of Jazz Pharmaceuticals PLC during the fourth quarter worth about $3,043,000. Raymond James Financial Services Advisors Inc. purchased a new position in Jazz Pharmaceuticals PLC during the fourth quarter valued at about $295,000. Dimensional Fund Advisors LP increased its position in Jazz Pharmaceuticals PLC by 0.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 147,511 shares of the specialty pharmaceutical company’s stock valued at $16,082,000 after buying an additional 408 shares during the last quarter. Credit Agricole S A increased its position in Jazz Pharmaceuticals PLC by 24.9% in the fourth quarter. Credit Agricole S A now owns 10,935 shares of the specialty pharmaceutical company’s stock valued at $1,193,000 after buying an additional 2,181 shares during the last quarter. Finally, Norges Bank purchased a new position in Jazz Pharmaceuticals PLC during the fourth quarter valued at about $61,558,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.
Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 152.80 on Wednesday. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The stock has a market capitalization of $9.17 billion, a price-to-earnings ratio of 23.09 and a beta of 1.11. The stock’s 50 day moving average is $151.80 and its 200 day moving average is $138.04.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing analysts’ consensus estimates of $1.42 by $0.01. The business had revenue of $376.10 million during the quarter, compared to analyst estimates of $376.58 million. Jazz Pharmaceuticals PLC had a net margin of 26.28% and a return on equity of 24.65%. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.26 earnings per share. On average, equities analysts forecast that Jazz Pharmaceuticals PLC will post $11.01 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/jazz-pharmaceuticals-plc-nasdaqjazz-stake-lowered-by-state-street-corp/1180099.html.
Several equities analysts recently issued reports on JAZZ shares. Zacks Investment Research downgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Mizuho cut their target price on Jazz Pharmaceuticals PLC from $150.00 to $144.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 31st. Cowen and Company reissued an “outperform” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, May 10th. Janney Montgomery Scott raised Jazz Pharmaceuticals PLC from a “neutral” rating to a “buy” rating and upped their target price for the company from $138.00 to $175.00 in a research report on Thursday, April 6th. Finally, Vetr downgraded Jazz Pharmaceuticals PLC from a “strong-buy” rating to a “buy” rating and set a $161.19 target price on the stock. in a research report on Monday, March 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $183.22.
In other news, SVP Karen J. Wilson sold 1,275 shares of the business’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $160.00, for a total transaction of $204,000.00. Following the transaction, the senior vice president now directly owns 21,133 shares in the company, valued at $3,381,280. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Suzanne Sawochka Hooper sold 2,500 shares of the business’s stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $160.00, for a total transaction of $400,000.00. Following the transaction, the executive vice president now owns 39,649 shares in the company, valued at $6,343,840. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 42,295 shares of company stock worth $6,516,538. 4.30% of the stock is currently owned by company insiders.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with our FREE daily email newsletter.